Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Everest Medicines's total inventories for the quarter that ended in Jun. 2026 was HK$175 Mil. Everest Medicines's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Jun. 2026 was HK$105 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Everest Medicines's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was HK$-1.93.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Everest Medicines's Days Inventory for the
six
months ended in Jun. 2026 was 47.69.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Everest Medicines's Inventory Turnover for the quarter that ended in Jun. 2026 was 3.83.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Everest Medicines's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.08.
Everest Medicines (HKSE:01952) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Everest Medicines's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Everest Medicines's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Everest Medicines Total Inventories Related Terms
Everest Medicines Total Inventories Historical Data
* Premium members only.
The historical data trend for Everest Medicines's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Everest Medicines (HKSE:01952) has a Total Inventories of HK$175 Mil as of Jun. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Everest Medicines and its competitors.
Is Everest Medicines' Total Inventories too high?
Everest Medicines' current Total Inventories is HK$175 Mil. Overall, Everest Medicines has a GF Score™ of 43/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Total Inventories compare to VRTX and REGN?
Everest Medicines' Total Inventories of HK$175 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Everest Medicines and its competitors. Everest Medicines's current Total Inventories is HK$175 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (HKSE:01952) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$211.34, compared to a current price of HK$31.44 — trading 85.1% below its estimated fair value. The current Total Inventories is HK$175 Mil. Everest Medicines' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Everest Medicines (HKSE:01952), the current Total Inventories is HK$175 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Medicines (HKSE:01952) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued.
The current stock price of HK$31.44 is trading 85.1% below its estimated GF Value™ of HK$211.34.
GuruFocus considers Everest Medicines to be Significantly Undervalued.
Key valuation signals for HKSE:01952:
Total Inventories: HK$175 Mil
GF Value™: HK$211.34 vs. price of HK$31.44 (85.1% below fair value)
No single metric tells the full story. See the HKSE:01952 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
43GF Score
Get the complete analysis for HKSE:01952
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01952 has been successfully added to your 
